Vivus’s (VVUS) Future Dependent On Qnexa

J.P.Morgan adjusted its estimates for Vivus Inc.,

to reflect the company's quarterly results and expense management for the remainder of the year given the uncertainty surrounding the Qnexa (obesity) panel. The firm believes that the cash balance of $175 million would provide some cushion in the event of delayed approval. The firm has maintained a Neutral rating for Vivus Inc. which reported in-line second quarter results. The upside catalysts to the stock include earlier than expected approval of Qnexa or a product partnership. The firm believes that despite the company’s pipeline of sexual health products, the future of Vivus is heavily dependent on the success or failure of Qnexa.